Pharmacological mechanisms underlying neurovascular alterations related to resistant and refractory migraine: CGRP pathways and beyond - PubMed

4 hours ago

Migraine is a leading global cause of disability, but 40% of patients do not respond to available treatments, including CGRP-targeted therapies.
Non-response is linked to clinical, genetic, and epigenetic factors affecting pharmacokinetics and pharmacodynamics, with CGRP and other neuropeptides playing a key role.
Understanding neurovascular mechanisms and exploring combination therapies may help overcome resistance and refractoriness, requiring further research for personalized treatments.

Hasty Briefsbeta